Combination treatment in HBeAg-negative chronic hepatitis B

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Chronic hepatitis B (CHB) is a significant global health concern, particularly HBeAg-negative CHB, linked to advanced liver disease.
• Current monotherapies, including interferon and nucleoside/nucleotide analogues, have limitations in treating CHB.
• Combination therapy has been proposed to enhance antiviral efficacy and reduce drug resistance.

Purpose of the Study:

• To evaluate the efficacy of combining interferon (pegylated) with long-term nucleoside/nucleotide analogues for CHB.
• To assess the effectiveness of combining newer analogues or nucleotide with nucleoside analogues.
• To review existing data on combination therapy versus monotherapy in CHB treatment.

Main Methods:

• Review of existing clinical studies on CHB combination therapy.
• Analysis of treatment outcomes comparing combination therapy with monotherapy.
• Consideration of study limitations, including small sample sizes and non-standard treatment durations.

Main Results:

• Existing data do not support the hypothesis that combination therapy increases antiviral efficacy in CHB.
• Combination treatment may reduce the risk of lamivudine resistance.
• Add-on therapy with adefovir or tenofovir is recommended for lamivudine-resistant CHB.

Conclusions:

• Combination therapy cannot be recommended as a first-line treatment for CHB until more data are available.
• Add-on therapy with adefovir or tenofovir is the preferred treatment for lamivudine-resistant CHB.
• Specific combinations like lamivudine/adefovir or adding tenofovir may be considered for CHB patients with cirrhosis or insufficient response to other treatments.